Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Factor H autoantibodies in membranoproliferative glomerulonephritis

Goodship, Timothy H.J., Pappworth, Isabel Y., Toth, Tibor, Denton, Mark, Houlberg, Kris, McCormick, Frances, Warland, David, Moore, Iain, Hunze, Eva-Maria, Staniforth, Scott J., Hayes, Christine, Cavalcante, Danielle Paixão, Kavanagh, David, Strain, Lisa, Herbert, Andrew P., Schmidt, Christoph Q., Barlow, Paul N., Harris, Claire Louise and Marchbank, Kevin J. 2012. Factor H autoantibodies in membranoproliferative glomerulonephritis. Molecular Immunology 52 (3-4) , pp. 200-206. 10.1016/j.molimm.2012.05.009

Full text not available from this repository.


Factor H autoantibodies are found in ∼10% of aHUS patients. Most are associated with complete deficiency of factor H related proteins 1/3 and bind to the C terminal recognition domain. MPGN, like aHUS, is characterised by complement activation. In this study we, therefore, examined the hypothesis that factor H autoantibodies are associated with MPGN. We screened sera from 16 MPGN patients and 100 normal controls using ELISA and detected strongly positive IgG factor H autoantibodies in 2 patients. One patient had type II (DDD) MPGN (male aged 24 yrs) with C3NeF and the other type I (female aged 26 yrs) with no detectable C3NeF. We identified the binding site of the autoantibodies using small SCR domain fragments in the ELISA and showed that the autoantibodies in both patients bound predominately to the N terminal complement regulatory domain of factor H. We measured CFHR 1/3 copy number using MLPA and showed that both patients had 2 copies of CFHR1 and 3. Finally, we examined the functionality of detected factor H autoantibodies using purified patient IgG and observed increased haemolysis when purified IgG from both patients was added to normal human sera prior to incubation with rabbit red blood cells. Thus, in a cohort of MPGN patients we have found a high titre of functionally significant factor H autoantibodies in two patients with MPGN. Antibody depleting therapy may have a role in such patients and we suggest that screening for factor H autoantibodies should be undertaken in all patients with MPGN.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Systems Immunity Research Institute (SIURI)
Subjects: Q Science > QR Microbiology > QR180 Immunology
R Medicine > R Medicine (General)
Uncontrolled Keywords: factor H, complement, MPGN, autoantibodies
Publisher: Elsevier
ISSN: 0161-5890
Last Modified: 04 Jun 2017 04:34

Citation Data

Cited 63 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item